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Purpose: Renal tumors consist of heterogeneous groups that frequently show complex 
and overlapping morphology, thus making it difficult to make a correct diagnosis. One 
of the most problematic differential diagnoses is to distinguish chromophobe renal cell 
carcinoma (RCC) from oncocytoma. These should be distinguished by differences in 
their behavior and clinical outcome. Our study was performed to identify whether cav-
eolin-1 and MOC-31 are useful immunohistochemical markers for differentiating chro-
mophobe RCC from oncocytoma.
Materials and Methods: We selected 23 chromophobe RCCs, 8 oncocytomas, and 25 
clear cell RCCs and performed immunohistochemical staining for caveolin-1 and 
MOC-31.
Results: Caveolin-1 was positive in 20 (87%) of 23 chromophobe RCCs, 0 of 8 oncocyto-
mas, and 21 (84%) of 25 clear cell RCCs. MOC-31 was positive in 22 (96%) of 23 chromo-
phobe RCCs, 2 (25%) of 8 oncocytomas, and 14 (56%) of 25 clear cell RCCs. There was 
a statistically significant difference in the expression of caveolin-1 and MOC-31 be-
tween chromophobe RCC and oncocytoma (p＜0.001). In addition, clear cell RCC was 
also significantly different from oncocytoma in the expression of caveolin-1 (p＜0.001) 
and was significantly different from chromophobe RCC in the expression of MOC-31 
(p＜0.001).
Conclusions: Caveolin-1 and MOC-31 can be useful markers in the differential diag-
nosis of chromophobe RCC, oncocytoma, and clear cell RCC.
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Renal neoplasms are composed of heterogeneous groups 
including clear cell renal cell carcinoma (RCC), papillary 
RCC, chromophobe RCC, collecting duct carcinoma, onco-
cytoma, and others. In most cases, these categories are 
easily differentiated from each other on the basis of histo-
logic features alone. Occasionally, however, there are over-
lapping morphological characteristics between such tu-
mors as well as histologic heterogeneity within a single 
tumor. In those cases, it may be difficult to make an accu-
rate subtyping of the tumors.
A diagnostic problem can arise in distinguishing chro-
mophobe RCC from oncocytoma. These two types of tumors 
have a common origin, distal nephrons, and similar pheno-
type, so it may be difficult to distinguish these tumors in 
the practice of diagnostic pathology. Chromophobe RCC 
and oncocytoma should be distinguished from each other 
because both tumors have different behaviors and clinical 
outcomes. Oncocytoma is a benign tumor, whereas chromo-
phobe RCC is a subtype of RCC, namely, malignant. In re-
cent years, several studies have been carried out to find Korean J Urol 2011;52:96-103
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  1 67/M 8.0 −− pT2a Done Diffuse positive Diffuse positive
  2 76/M 5.4 −− pT1b Not done Diffuse positive Negative
  3 47/F 4.5 −− pT1b Done Diffuse positive Diffuse positive
  4 64/M 3.7 −− pT1a Done Negative Diffuse positive
  5 70/M 9.5 −− pT2a Not done Diffuse positive Diffuse positive
  6 49/M 5.0 −− pT1b Not done Diffuse positive Diffuse positive
  7 41/F 7.2 −− pT2a Not done Diffuse positive Diffuse positive
  8 17/M 8.0 −− pT2a Not done Diffuse positive Diffuse positive
  95 9 / M 1 5 . 0 −− pT2b Not done Diffuse positive Diffuse positive
10 43/F 10.0 −− pT2a Not done Diffuse positive Diffuse positive
11 65/M 3.5 −− pT1a Not done Diffuse positive Diffuse positive
12 63/F 6.5 −− pT2b Not done Diffuse positive Diffuse positive
13 41/F 5.0 −− pT1b Not done Diffuse positive Diffuse positive
14 39/F 24.0 ＋＋ pT4 Not done Negative Diffuse positive
15 64/M 2.2 −− pT1a Not done Diffuse positive Diffuse positive
16 49/F 4.4 −− pT1b Not done Diffuse positive Diffuse positive
17 41/F 2.5 ＋ − pT3a Not done Negative Diffuse positive
18 43/F 3.3 −− pT1a Not done Diffuse positive Diffuse positive
19 40/F 5.0 −− pT1b Not done Diffuse positive Diffuse positive
20 65/M 13.0 ＋＋ pT3a Not done Diffuse positive Diffuse positive
21 49/F 11.5 −− pT2b Not done Diffuse positive Diffuse positive
22 42/M 5.0 − ＋ pT3a Not done Diffuse positive Diffuse positive
23 77/M 5.0 ＋＋ pT3a Not done Diffuse positive Diffuse positive
Oncocytoma
  1 46/M 4.5 −− Done Negative Negative
  2 68/M 5.8 −− Done Negative Negative
  3 65/F 3.5 −− Not done Negative Negative
  4 80/F 2.7 −− Done Negative Negative
  5 38/M 3.0 −− Not done Negative Negative
  6  45/F 2.0 −− Done Negative Negative
  7 52/F 4.4 −− Not done Negative Diffuse positive
  8 64/F 5.0 −− Not done Negative Diffuse postive
RCC: renal cell carcinoma, EM: electron microscopic examination, M: male, F: female
helpful ancillary means to distinguish chromophobe RCC 
from oncocytoma. However, the results of these studies are 
inconsistent and still unsatisfactory [1-8].
Caveolin-1, a 24-kd membrane protein, is a major struc-
tural and functional protein component of caveolae, endo-
cytic structures of the cell membrane [9,10]. Caveolin-1 
plays important roles in membrane traffic, lipid traffic, and 
signal transduction [9,10]. Several studies have shown that 
the expression of caveolin-1 is elevated in various types of 
malignancies such as prostate, breast, colon, esophagus, 
and urinary bladder cancers [11-14], but the precise roles 
of caveolin-1 in carcinogenesis are still unclear.
MOC-31 is a kind of cell surface glycoprotein and is ex-
pressed in most benign and malignant epithelia. It is 
known that MOC-31 is useful for distinguishing adeno-
carcinoma from mesothelioma as well as hepatocellular 
carcinoma from cholangiocarcinoma and metastatic ad-
enocarcinoma in the liver [15,16].
In this study, we intended to identify whether there were 
any differences in immunohistochemical reactivity for cav-
eolin-1 and MOC-31 between chromophobe RCC and onco-
cytoma and to determine whether the expression of these 
proteins has a benefit as useful immunohistochemical 
markers in distinguishing the tumors. In addition, clear 
cell RCC, particularly the granular cell type, may also have 
a phenotype similar to the previously mentioned two types 
of tumors and cause a diagnostic problem. Accordingly, we 
also investigated the immunohistochemical reactivity of 
clear cell RCC for caveolin-1 and MOC-31 and evaluated 




Twenty-three chromophobe RCCs and 8 oncocytomas were 
retrieved from the surgical pathology archives between 
1997 and 2006 at three institutes. Twenty-five clear cell Korean J Urol 2011;52:96-103
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Parietal epithelium ＋ −
Proximal tubule −−
Distal tubule  − ＋
Collecting duct − ＋
Endothelial cell ＋ −
Smooth muscle cell ＋ −
FIG. 1. Expression of caveolin-1 and MOC-31 in normal kidney tissue. (A) Caveolin-1 is expressed in parietal epithelial cells of Bowman 
capsules, endothelial cells, and smooth muscle cells of blood vessels. (B) MOC-31 is expressed only in epithelial cells of distal tubules.
RCCs, including 10 cases of clear cell type and 15 cases of 
granular cell type, were also selected from the surgical 
pathology files of one institute. Those cases were composed 
of only radical surgical specimens. Two pathologists, one 
of whom has expertise in genitourinary pathology, re-
viewed all cases and achieved consensus on classification 
according to the recommendations of the International 
Union Against Cancer [17] and the World Health Organi-
zation Classification of Tumors [18]. Most tumors were 
categorized on the basis of light microscopic histology. 
Electron microscopic examination was performed for 9 cas-
es because they showed obscure and overlapping histologic 
features on light microscopic, histochemical, and im-
munohistochemical examinations. Two cases having un-
clear features despite the electron microscopic examina-
tion were excluded from this study. Staging of chromo-
phobe RCC was performed according to the recently up-
dated staging system (7th edition) of the American Joint 
Committee on Cancer (AJCC) (7th edition) and the Union 
Internationale Contre le Cancer (UICC) [19]. The clin-
icopathologic data of all chromophobe RCCs and oncocyto-
mas are summarized in Table 1.
2. Immunohistochemistry
The immunohistochemical staining was performed with 
the DAKO EnVision Kit (Dako, Denmark) on sections pre-
pared from formalin-fixed and paraffin-embedded speci-
mens that were dewaxed and rehydrated with graded con-
centrations of alcohol. Endogenous peroxidase was blocked 
by dipping the sections in 3% aqueous hydrogen peroxide 
for 10 min, and antigen retrieval was performed with a 
10-min microwave treatment in 10 mmol/l citrate buffer, 
pH 6.0. For immunohistochemical staining of MOC-31, 
Target Retrieval Solution (Dako, Denmark) was used for 
antigen retrieval. Diluted primary antibodies for cav-
eolin-1 (1:200, Transduction Laboratories, US) and MOC- 
31 (1:50, Dako, Denmark) were treated at room temper-
ature for 30 min and 1 h, respectively. After the primary 
antibody incubation, the sections were incubated with the 
secondary antibody. The sections were lightly counter-
stained with hematoxylin.
Immunoreactivity for caveolin-1 and MOC-31 was con-
sidered as diffuse positive when 50% or more of the tumor 
cells were stained, as focal positive when 10% to 49% of the 
tumor cells were stained, and as negative when less than 
10% of the tumor cells were stained. Internal positive con-
trols were endothelial cells and distal tubular epithelial 
cells for caveolin-1 and MOC-31, respectively.
3. Statistical analysis
Data were analyzed by the Fisher’s exact test with SPSS 
ver. 12.0 (SPSS Inc., Chicago, IL, USA) to evaluate correla-
tion between the tumor types and expression of immuno-
histochemical stain for caveolin-1 and MOC-31. p-values 
less than 0.05 were considered statistically significant.
RESULTS
1. Immunoreactivity for Caveolin-1
In normal kidney tissue, expression of caveolin-1 was seen Korean J Urol 2011;52:96-103
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FIG. 2. Expression of caveolin-1 in chromophobe renal cell carcinoma and oncocytoma. (A) Chromophobe renal cell carcinoma is 
diffuse, moderate to strong positive for caveolin-1, showing granular and cytoplasmic staining with membranous condensation. (B) 
Oncocytoma is negative for caveolin-1.
FIG. 3. Expression of caveolin-1 in clear cell renal cell carcinoma. (A) Clear cell type shows membranous staining of caveolin-1. (B) 
Granular cell type shows diffuse cytoplasmic staining with membranous condensation similar to chromophobe renal cell carcinoma.
in parietal epithelia of Bowman capsules, endothelial cells, 
and smooth muscle cells of blood vessels but not in endothe-
lial cells of glomeruli or any other epithelia (Table 2, Fig. 
1A).
In chromophobe RCCs, 20 (87%) of 23 cases showed dif-
fuse positivity for caveolin-1. All positive cases showed ex-
pression of caveolin-1 in 90% or more of the tumor cells and 
moderate to strong intensity except for one case that had 
relatively weak intensity. The pattern of immunohisto-
chemical staining was diffusely cytoplasmic and granular. 
In most of the cases, the cell membrane was also stained 
and the staining intensity was stronger in the membrane 
than in the cytoplasm (Fig. 2A). In the three negative cases, 
none of the tumor cells expressed caveolin-1. 
Oncocytomas showed negative results for caveolin-1 in 
all eight cases (Fig. 2B). None of the tumor cells expressed 
caveolin-1 except for one case in which caveolin-1 was ex-
pressed in only 5% or less of the tumor cells.
Clear cell RCCs were diffuse positive in 19, focal positive 
in 2, and negative in 4. The total number of positive cases 
was 21 (84%) of 25 clear cell RCCs. All 10 cases of the clear 
cell type were diffuse positive, whereas 9 (60%) of 15 cases 
of the granular cell type were diffuse positive. There was 
a slight difference in the pattern of immunohistochemical 
staining between the clear and granular cell types. All cas-
es of the clear cell type showed dominantly membranous 
staining without cytoplasmic staining (Fig. 3A), whereas 
most cases of the granular cell type exhibited a similar 
staining pattern to that of chromophobe RCC, namely, a 
diffusely cytoplasmic and granular pattern with focal 
membranous condensation (Fig. 3B).
The incidence of caveolin-1 expression showed statisti-Korean J Urol 2011;52:96-103
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TABLE 3. Results of immunohistochemical staining for caveolin-1 and MOC-31
Caveolin-1, n (%) MOC-31, n (%)
Negative Focal positive Diffuse positive Negative Focal positive Diffuse positive
Chromophobe RCC (n=23) 3 (13) 0 (0) 20 (87)   1 (4)  0 (0) 22 (96)
Oncocytoma (n=8) 8 (100) 0 (0)   0 (0)   6 (75) 0 (0)   2 (25)
Clear cell RCC (n=25) 4 (16) 2 (8) 19 (76) 11 (44) 2 (8) 12 (48)
Clear (n=10) 0 (0) 0 (0) 10 (100)   2 (20) 0 (0)   8 (80)
Granular (n=15) 4 (27) 2 (13)   9 (60)   9 (60) 2 (13)   4 (27)
RCC: renal cell carcinoma











Caveolin-1 ＜0.001 0.466 ＜0.001
MOC-31 ＜0.001 ＜0.001 0.215
RCC: renal cell carcinoma
FIG. 4. Expression of MOC-31 in chromophobe renal cell carcinoma and oncocytoma. (A) Chromophobe renal cell carcinoma shows 
diffuse, strong, and membranous staining for MOC-31. (B) Oncocytoma shows no staining for MOC-31.
cally significant differences between chromophobe RCCs 
and oncocytomas (p＜0.001) and between clear cell RCCs 
and oncocytomas (p＜0.001) but not between chromophobe 
and clear cell RCCs (p=0.466) (Table 3, 4).
2. Immunoreactivity for MOC-31 
MOC-31 was positive in distal tubules and collecting ducts 
of normal kidney tissue but negative in other epithelial and 
mesenchymal tissues (Table 2, Fig. 1B).
MOC-31 was diffuse positive in 22 (96%) of 23 chromo-
phobe RCCs, showing a strong membranous pattern of im-
munohistochemical staining (Fig. 4A), and negative in only 
1 case.
In oncocytomas, MOC-31 was negative in 6 of 8 cases and 
diffuse positive in the other 2 cases (25%) (Fig. 4B). Three 
of the six negative cases expressed MOC-31 in less than 
10% of the tumor cells, and the other three cases showed 
no staining. In the former three cases, MOC-31 was charac-
teristically expressed in the tumor cells showing tubular 
structures but not solid nests or trabecular structures. In 
addition, two oncocytomas showing diffuse expression of 
MOC-31 were composed of predominantly tubular struc-
tures, and solid or trabecular structures were only a minor 
portion. MOC-31 was expressed in such tubular structures 
rather than in solid or trabecular structures (Fig. 5).
Clear cell RCCs showed relatively variable MOC31 
staining results. Clear cell RCCs were diffuse positive for 
MOC-31 in 12, focal positive in 2, and negative in 11. The 
total number of positive cases was 14 (56%) of 25 cases. In 
particular, the granular cell type of clear cell RCC showed 
less positivity for MOC-31 than did the clear cell type. Only 
6 (40%) of 15 cases of the granular cell type were positive 
for MOC-31. All positive cases showed a membranous 
staining pattern as for the chromophobe RCCs. 
The incidence of MOC-31 expression showed statisti-
cally significant differences between chromophobe RCCs 
and oncocytomas (p＜0.001) and between chromophobe 
and clear cell RCCs (p＜0.001) but not between clear cell Korean J Urol 2011;52:96-103
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FIG. 5. Expression of MOC-31 in oncocytoma with tubular differen-
tiation. In a few cases of oncocytomas, MOC-31 is expressed in the 
tumor cells showing tubular differentiation but not solid or 
trabecular nests.
RCCs and oncocytomas (p=0.215) (Table 3, 4).
DISCUSSION
Subtypes of renal cell tumors are various and complex. 
Although each renal cell tumor has unique characteristics, 
they may occasionally have overlapping histologic features 
that make it difficult to make a proper diagnosis. One of the 
most problematic differential diagnoses is to distinguish 
chromophobe RCC from oncocytoma.
Chromophobe RCC was first described by Thoenes et al 
in 1985 [20]. Chromophobe RCC consists of tumor cells 
showing abundant pale cytoplasm with a perinuclear halo 
and peripheral condensation and hyperchromatic, irregu-
lar, wrinkled nuclei. By contrast, oncocytomas have tumor 
cells showing abundant eosinophilic granular cytoplasm 
and regular and round nuclei. Both tumors can be dis-
tinguished on the basis of these histologic features. 
However, occasionally, when the tumors show obscure mi-
croscopic findings, it can be difficult to make a differential 
diagnosis. Therefore, many investigators have searched 
for helpful ancillary means to discriminate these two types 
of renal tumors. 
Electron microscopic examination is an important and 
useful tool in the differential diagnosis of chromophobe 
RCC and oncocytoma. However, electron microscopic ex-
amination is technically difficult, expensive, and not avail-
able in many laboratories. Several studies have suggested 
that Hale's colloidal iron stain is helpful for the differential 
diagnosis of chromophobe RCC from oncocytoma [1]. 
However, Hale's colloidal iron stain is also technically de-
manding and difficult to interpret, and therefore reprodu-
cibility is relatively low [2].
Several studies with various immunohistochemical 
markers, including kidney-specific cadherin, CK7, EMA, 
CD10, parvalbumin, RCC, c-KIT, and RON proto-onco-
gene, have been performed to find useful markers for dis-
tinguishing chromophobe RCC from oncocytoma. However, 
the results of these studies are inconsistent or turned out 
to be not satisfactory. Accordingly, the use of these markers 
in differential diagnosis is limited [2-8,21,22].
Caveolin-1 is a major protein component of caveolae, 
which are endocytic structures of the cell membrane, and 
is localized to the cytosolic surface of caveolae. Caveolin-1 
interacts with both lipids and lipid anchors on proteins; 
therefore, it has multiple functions in signal transduction, 
membrane traffic, and intracellular and extracellular lipid 
transport [9,10]. Expression of this molecule has been stud-
ied in various types of tumors, including prostate, breast, 
colon, esophagus, and urinary bladder cancers [11-14]. 
However, only a small number of studies have recently re-
ported a relationship between the expression of caveolin-1 
and renal neoplasms, including chromophobe RCC and on-
cocytoma [23-25].
In the present study, caveolin-1 was expressed in 20 
(87%) of 23 chromophobe RCCs but in 0 of 8 oncocytomas. 
All positive cases of chromophobe RCC showed diffuse, 
moderate to strong staining in 90% or more of tumor cells 
and cytoplasmic and granular staining with membranous 
condensation. This clear discrimination enables the use of 
caveolin-1 for differential diagnosis between chromophobe 
RCC and oncocytoma (p＜0.001).
Carrion et al and Mete et al reported that most oncocyto-
mas express caveolin-1 with a diffuse cytoplasmic staining 
pattern and that chromophobe RCCs show a relatively de-
creased expression of caveolin-1 [23,24]. This difference 
probably originated from the artifact that they did not use 
a blocking step for endogenous biotin despite using an avi-
din-biotin peroxidase kit. Endogenous biotin in oncocyto-
mas may cause a false-positive result. Nevertheless, there 
was a difference in staining pattern between chromophobe 
RCCs and oncocytomas in their studies. According to them, 
chromophobe RCCs showed peripheral cytoplasmic stain-
ing, whereas oncocytomas showed diffuse cytoplasmic 
staining. There was an obvious difference in the incidence 
and staining pattern of caveolin-1 expression between both 
tumors.
In contrast with these findings, Garcia and Li reported 
that caveolin-1 was positive in all 21 chromophobe RCCs 
but was focal positive, with staining in less than 20% of the 
tumor cells, in only 3 of 26 oncocytomas [25]. This result 
is consistent with and supports our result.
Occasionally, it may also be difficult to distinguish clear 
cell RCC, particularly the granular cell type, from chromo-
phobe RCC or oncocytoma in practice. Therefore, our pres-
ent study also included clear cell RCCs. Twenty-one (84%) 
of 25 clear cell RCCs were positive for caveolin-1, including 
2 focal positive cases. Granular cell type tumors of clear cell 
RCCs were very similar to chromophobe RCC in staining 
pattern as well as extent, whereas clear cell type tumors 
differed from chromophobe RCC, that is, showing mem-
branous staining. On the basis of these results, the gran-
ular cell type of clear cell RCC could be differentiated from Korean J Urol 2011;52:96-103
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oncocytoma (p＜0.001) but not chromophobe RCC (p= 
0.466).
MOC-31, a kind of cell surface glycoprotein, is expressed 
in various benign and malignant epithelia, but its function 
is still unclear. MOC-31 has been studied for differential 
diagnosis between hepatocellular carcinoma and chol-
angiocarcinoma or metastatic adenocarcinoma in the liver 
or between mesothelioma and adenocarcinoma [15,16]. 
Studies associated with renal neoplasms have rarely been 
performed.
In our study, MOC-31 showed diffuse, strong, and mem-
branous staining in 22 (96%) of 23 chromophobe RCCs and 
diffuse cytoplasmic staining in only 2 (25%) of 8 oncocy-
tomas. The other six cases of oncocytomas were considered 
to be negative, but three of them expressed MOC31 with 
cytoplasmic staining in less than 10% of the tumor cells. 
In these three cases and the diffuse positive two cases of 
oncocytomas, MOC-31 was predominantly expressed in 
the tumor cells showing tubular differentiation rather 
than solid or trabecular structures. This seems to be related 
to the fact that MOC-31 is expressed in distal tubular cells 
of normal kidney. Although most oncocytomas do not ex-
press MOC-31, some oncocytomas may express MOC-31 if 
they are differentiated toward tubules and have similar 
structural features to normal distal tubules. Further mo-
lecular analysis is needed to uncover the precise function 
of MOC-31 in tubular differentiation and tumorigenesis.
According to our result for MOC31 expression, diffuse 
membranous expression of MOC-31 is a feature of chromo-
phobe RCC rather than of oncocytoma, particularly not 
showing tubular differentiation (p＜0.001). Pan et al 
showed that 23 (82%) of 28 chromophobe RCCs were pos-
itive for MOC-31, whereas all 7 oncocytomas were com-
pletely negative [7]. This result is consistent with ours.
Clear cell RCCs expressed MOC-31 in 14 (56%) of 25 cas-
es, including 2 focal positive cases. Considering only the 
granular cell type, 6 (40%) of 15 cases were positive for 
MOC-31. As previously mentioned, clear cell RCC had a 
statistically significant difference in the expression of 
MOC-31 from chromophobe RCC (p＜0.001) but not onco-
cytoma (p=0.215). For example, if a tumor is negative for 
MOC-31, it is more likely to be clear cell RCC than chromo-
phobe RCC.
CONCLUSIONS
The results of the present study showed an obvious discrim-
ination between chromophobe RCC and oncocytoma in the 
expression of caveolin-1 and MOC-31. In other words, these 
immunohistochemical markers are thought to be consid-
erably useful for distinguishing these tumors. In addition, 
clear cell RCC also showed a different expression of cav-
eolin-1 and MOC-31 from oncocytoma and chromophobe 
RCC, respectively. If used together with other known 
markers such as c-KIT or RCC marker, both caveolin-1 and 
MOC-31 may be helpful in the differentiation of clear cell 
RCC from chromophobe RCC or oncocytoma.
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